Doods H - Search Results

1

Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy.

Michel MC, Gaida W, Beck-Sickinger AG, Wieland HA, Doods H, Dürr H, Jung G, Schnorrenberg G. Michel MC, et al. Among authors: doods h. Mol Pharmacol. 1992 Oct;42(4):642-8. Mol Pharmacol. 1992. PMID: 1331755

2

Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.

Doods HN, Wienen W, Entzeroth M, Rudolf K, Eberlein W, Engel W, Wieland HA. Doods HN, et al. J Pharmacol Exp Ther. 1995 Oct;275(1):136-42. J Pharmacol Exp Ther. 1995. PMID: 7562541

3

The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226.

Rudolf K, Eberlein W, Engel W, Wieland HA, Willim KD, Entzeroth M, Wienen W, Beck-Sickinger AG, Doods HN. Rudolf K, et al. Among authors: doods hn. Eur J Pharmacol. 1994 Dec 27;271(2-3):R11-3. doi: 10.1016/0014-2999(94)90822-2. Eur J Pharmacol. 1994. PMID: 7705422

4

Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents.

Wieland HA, Engel W, Eberlein W, Rudolf K, Doods HN. Wieland HA, et al. Among authors: doods hn. Br J Pharmacol. 1998 Oct;125(3):549-55. doi: 10.1038/sj.bjp.0702084. Br J Pharmacol. 1998. PMID: 9806339 Free PMC article.

5

Effects of the neuropeptide Y Y(2) receptor antagonist BIIE0246 on presynaptic inhibition by neuropeptide Y in rat hippocampal slices.

Weiser T, Wieland HA, Doods HN. Weiser T, et al. Among authors: doods hn. Eur J Pharmacol. 2000 Sep 15;404(1-2):133-6. doi: 10.1016/s0014-2999(00)00478-7. Eur J Pharmacol. 2000. PMID: 10980271

6

BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist.

Doods H, Gaida W, Wieland HA, Dollinger H, Schnorrenberg G, Esser F, Engel W, Eberlein W, Rudolf K. Doods H, et al. Eur J Pharmacol. 1999 Nov 19;384(2-3):R3-5. doi: 10.1016/s0014-2999(99)00650-0. Eur J Pharmacol. 1999. PMID: 10611450

7

The SK-N-MC cell line expresses an orexin binding site different from recombinant orexin 1-type receptor.

Wieland HA, Söll RM, Doods HN, Stenkamp D, Hurnaus R, Lämmle B, Beck-Sickinger AG. Wieland HA, et al. Eur J Biochem. 2002 Feb;269(4):1128-35. doi: 10.1046/j.0014-2956.2001.02739.x. Eur J Biochem. 2002. PMID: 11856342 Free article.

8

Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.

Wieland HA, Willim KD, Entzeroth M, Wienen W, Rudolf K, Eberlein W, Engel W, Doods HN. Wieland HA, et al. Among authors: doods hn. J Pharmacol Exp Ther. 1995 Oct;275(1):143-9. J Pharmacol Exp Ther. 1995. PMID: 7562543

9

Labeling of neuropeptide Y receptors in SK-N-MC cells using the novel, nonpeptide Y1 receptor-selective antagonist [3H]BIBP3226.

Entzeroth M, Braunger H, Eberlein W, Engel W, Rudolf K, Wienen W, Wieland HA, Willim KD, Doods HN. Entzeroth M, et al. Among authors: doods hn. Eur J Pharmacol. 1995 May 24;278(3):239-42. doi: 10.1016/0014-2999(95)00161-d. Eur J Pharmacol. 1995. PMID: 7589160

10

Adrenomedullin mediates vasodilation via CGRP1 receptors.

Entzeroth M, Doods HN, Wieland HA, Wienen W. Entzeroth M, et al. Among authors: doods hn. Life Sci. 1995;56(1):PL19-25. doi: 10.1016/0024-3205(94)00412-l. Life Sci. 1995. PMID: 7830489

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters